Atherosclerosis Risk Factors in Patients with Reactive Hypoglycemia

References

• Libby P, Buring JE, Badimon L., et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. doi:10.1038/s41572-019-0106-z
   PubMed Web of Science ®Google Scholar
• Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The Diabetes Mellitus-Atherosclerosis Connection: the Role of Lipid and Glucose Metabolism and Chronic Inflammation. Int J Mol Sci. 2020;21(5):1835. doi:10.3390/ijms21051835
   PubMed Web of Science ®Google Scholar
• Tanasijevic MJ, Cannon CP, Wybenga DR, et al. Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A. Am Heart J. 1997;134(4):622–630. doi:10.1016/S0002-8703(97)70044-9
   Web of Science ®Google Scholar
• Tanasijevic MJ, Cannon CP, Antman EM, et al. Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B. J Am Coll Cardiol. 1999;34(3):739–747. doi:10.1016/S0735-1097(99)00274-0
   Web of Science ®Google Scholar
• Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation. 2001;104(23):2778–2783. doi:10.1161/hc4801.100236
   Web of Science ®Google Scholar
• Goff DC, Gerstein HC, Ginsberg HN, et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99(12A):4i–20i. doi:10.1016/j.amjcard.2007.03.002
   PubMed Web of Science ®Google Scholar
• Bhadriraju S, Ray KK, DeFranco AC, et al. Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. Am J Cardiol. 2006;97(11):1573–1577. doi:10.1016/j.amjcard.2005.12.046
   Web of Science ®Google Scholar
• Yang SW, Park KH, Zhou YJ. The Impact of Hypoglycemia on the Cardiovascular System: physiology and Pathophysiology. Angiology. 2016;67(9):802–809. doi:10.1177/0003319715623400
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Yoshida M, Yamada H, et al. Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk. Heart Vessels. 2015;30(4):469–476. doi:10.1007/s00380-014-0502-y
   Web of Science ®Google Scholar
• Jialal I, Dhindsa S. Hypoglycemia and the predisposition to cardiovascular disease: is the pro-inflammatory-pro-coagulant diathesis a plausible explanation? Atherosclerosis. 2016;251:504–506. doi:10.1016/j.atherosclerosis.2016.06.006
   Web of Science ®Google Scholar
• Rao AD, Bonyhay I, Dankwa J, et al. Baroreflex Sensitivity Impairment During Hypoglycemia: implications for Cardiovascular Control. Diabetes. 2016;65(1):209–215. doi:10.2337/db15-0871
   Web of Science ®Google Scholar
• Fitzpatrick C, Chatterjee S, Seidu S, et al. Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20(9):2169–2178. doi:10.1111/dom.13348
   PubMed Web of Science ®Google Scholar
• Amiel SA, Aschner P, Childs B; International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019;7(5):385–396. doi:10.1016/S2213-8587(18)30315-2
   PubMed Web of Science ®Google Scholar
• Sankar A, Khodai T, McNeilly AD, et al. Experimental Models of Impaired Hypoglycaemia-Associated Counter-Regulation. Trends Endocrinol Metab. 2020;31(9):691–703. doi:10.1016/j.tem.2020.05.008
   Web of Science ®Google Scholar
• EikFilho W, Marcon SS, Krupek T, et al. Blood levels of pro-inflammatory and anti-inflammatory cytokines during an oral glucose tolerance test in patients with symptoms suggesting reactive hypoglycemia. Braz J Med Biol Res. 2016;49(8):e5195. doi:10.1590/1414-431x20165195
   Web of Science ®Google Scholar
• Joy NG, Tate DB, Younk LM, Davis SN. Effects of Acute and Antecedent Hypoglycemia on Endothelial Function and Markers of Atherothrombotic Balance in Healthy Humans. Diabetes. 2015;64(7):2571–2580. doi:10.2337/db14-1729
   Web of Science ®Google Scholar
• Murata M, Adachi H, Oshima S, Kurabayashi M. Asymptomatic Reactive Hypoglycemia and Inflammatory Reaction in Patients with Coronary Artery Disease. Int Heart J. 2018;59(4):705–712. doi:10.1536/ihj.17-245
   Web of Science ®Google Scholar
• Çiftçi FC, Tuğcu AU, Çiftçi Ö. Sub-clinic atherosclerosis in patients with postprandial reactive hypoglycemia. Ann Med Res. 2019;26(12):2941–2947. doi:10.5455/annalsmedres.2019.10.609
   Google Scholar
• American Diabetes Association. 6. Glycemic Targets: standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl1):S73–S84. doi:10.2337/dc21-S006
   Web of Science ®Google Scholar
• Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2011;34(5):1164–1170. doi:10.2337/dc10-1915
   PubMed Web of Science ®Google Scholar
• Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94(3):709–728. doi:10.1210/jc.2008-1410
   PubMed Web of Science ®Google Scholar
• Edwards MK, Blaha MJ, Loprinzi PD. Atherogenic Index of Plasma and Triglyceride/High-Density Lipoprotein Cholesterol Ratio Predict Mortality Risk Better Than Individual Cholesterol Risk Factors, Among an Older Adult Population. Mayo Clin Proc. 2017;92(4):680–681. doi:10.1016/j.mayocp.2016.12.018
   PubMed Web of Science ®Google Scholar
• Noble-Campbell T. Atherogenic Index in Plasma and Risk of Cardiovascular Events [Dissertation]. Accra: University of Otago; 2019.
   Google Scholar
• Akici N, Onal ZE, Gürbüz T, Sağ C, Kilinç S. ATHEROGENIC INDICES IN THE ASSESSMENT OF CARDIOVASCULAR DISEASE RISK IN CHILDREN WITH OBESITY AND SUBCLINICAL HYPOTHYROIDISM. Acta Endocrinol. 2020;16(3):334–338. doi:10.4183/aeb.2020.334
   Google Scholar
• Guo J, Wang A, Wang Y, et al. Non-traditional Lipid Parameters as Potential Predictors of Asymptomatic Intracranial Arterial Stenosis. Front Neurol. 2021;12:679415. doi:10.3389/fneur.2021.679415
   Web of Science ®Google Scholar
• Nwagha UI, Ikekpeazu EJ, Ejezie FE, Neboh EE, Maduka IC. Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. Afr Health Sci. 2010;10(3):248–252.
   PubMed Web of Science ®Google Scholar
• Fernández-Macías JC, Ochoa-Martínez AC, Varela-Silva JA, Pérez-Maldonado IN. Atherogenic Index of Plasma: novel Predictive Biomarker for Cardiovascular Illnesses. Arch Med Res. 2019;50(5):285–294. doi:10.1016/j.arcmed.2019.08.009
   PubMed Web of Science ®Google Scholar
• Tang Q, Li X, Song P, Xu L. Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: developments in research and prospects for the future. Drug Discov Ther. 2015;9(6):380–385. doi:10.5582/ddt.2015.01207
   PubMed Web of Science ®Google Scholar
• Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab. 2015;19(1):160–164. doi:10.4103/2230-8210.146874
   PubMedGoogle Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Altuntaş Y. Postprandial Reactive Hypoglycemia. Sisli Etfal Hastan Tip Bul. 2019;53(3):215–220. doi:10.14744/SEMB.2019.59455
   PubMed Web of Science ®Google Scholar
• Hall M, Walicka M, Traczyk I. Hipoglikemia reaktywna jako choroba XXI wieku w ujęciu interdyscyplinarnym [Reactive hypoglycemia - an interdisciplinary approach of the disease of XXI Century]. Wiad Lek. 2020;73(2):384–389. [ Polish]. doi:10.36740/WLek202002134
   PubMedGoogle Scholar
• Bansal N, Weinstock RS, et al. Non-Diabetic Hypoglycemia. In: Feingold KR, Anawalt B, Boyce A, editors. Endotext. South Dartmouth (MA): MDText.com, Inc; 2020.
   Google Scholar
• Hall M, Walicka M, Panczyk M, Traczyk I. Metabolic Parameters in Patients with Suspected Reactive Hypoglycemia. J Pers Med. 2021;11(4):276. doi:10.3390/jpm11040276
   Web of Science ®Google Scholar
• Lv X, Fang K, Hao W, Han Y, Yang N, Yu Q. Identification of Reactive Hypoglycemia with Different Basic BMI and Its Causes by Prolonged Oral Glucose Tolerance Test. Diabetes Metab Syndr Obes. 2020;13:4717–4726. doi:10.2147/DMSO.S280084
   PubMed Web of Science ®Google Scholar
• Halama A, Kahal H, Bhagwat AM, et al. Metabolic and proteomic signatures of hypoglycaemia in type 2 diabetes. Diabetes Obes Metab. 2019;21(4):909–919. doi:10.1111/dom.13602
   Web of Science ®Google Scholar
• Rhyu YA, Jang JY, Park S, et al. Impaired Cortisol and Growth Hormone Counterregulatory Responses among Severe Hypoglycemic Patients with Type 2 Diabetes Mellitus. Endocrinol Metab. 2019;34(2):187–194. doi:10.3803/EnM.2019.34.2.187
   Web of Science ®Google Scholar
• Anogeianaki A, Angelucci D, Cianchetti E, et al. Atherosclerosis: a classic inflammatory disease. Int J Immunopathol Pharmacol. 2011;24(4):817–825. doi:10.1177/039463201102400401
   Web of Science ®Google Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. doi:10.1093/eurheartj/ehab484
   PubMed Web of Science ®Google Scholar
• Strisciuglio T, Izzo R, Barbato E, et al. Insulin Resistance Predicts Severity of Coronary Atherosclerotic Disease in Non-Diabetic Patients. J Clin Med. 2020;9(7):2144. doi:10.3390/jcm9072144
   Web of Science ®Google Scholar
• Di Pino A, DeFronzo RA. Insulin Resistance and Atherosclerosis: implications for Insulin-Sensitizing Agents. Endocr Rev. 2019;40(6):1447–1467. doi:10.1210/er.2018-00141
   PubMed Web of Science ®Google Scholar
• Farnier M, Zeller M, Masson D, Cottin Y. Triglycerides and risk of atherosclerotic cardiovascular disease: an update. Arch Cardiovasc Dis. 2021;114(2):132–139. doi:10.1016/j.acvd.2020.11.006
   Web of Science ®Google Scholar